CompletedPhase 4

AlmegaPL CV Health Open Label Study

United States250 participantsStarted 2022-05-11

Plain-language summary

The aim of this study is to assess the effectiveness of Almega PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA), on improving blood markers associated with heart health of iwi customers.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * New iwi/AlmegaPL subscribers. Exclusion Criteria: * Participants that are already taking AlmegaPL. * Participants with serious conditions including but not limited to kidney, neurological, immunological, liver and gastrointestinal disease, any heart condition or diabetes). * Any participant attempting conception, pregnant or breastfeeding

What they're measuring

Triglyceride change from baseline

Timeframe: From Baseline to Month 6

Trial details

NCT IDNCT05267301

SponsorQualitas Health

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-11-14

View on ClinicalTrials.gov More Cholesterol trials